Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Lett. 2013 Jul 28;335(2):404-11. doi: 10.1016/j.canlet.2013.02.059. Epub 2013 Mar 7.

Different administration strategies with paclitaxel induce distinct phenotypes of multidrug resistance in breast cancer cells.

Author information

1
Program of Innovative Cancer Therapeutics, Organ Transplantation Center of Zhejiang Province, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.

Abstract

Both dose-dense and dose-escalation chemotherapy are administered in clinic. By approximately imitating the schedules of dose-dense and dose-escalation administration with paclitaxel, two novel multidrug resistant (MDR) cell lines Bads-200 and Bats-72 were successfully developed from drug-sensitive breast cancer cell line BCap37, respectively. Different from Bads-200, Bats-72 exhibited stable MDR and significantly enhanced migratory and invasive properties, indicating that they represented two different MDR phenotypes. Our results showed that distinct phenotypes of MDR could be induced by altered administration strategies with a same drug. Administrating paclitaxel in conventional dose-escalation schedule might induce recrudescent tumor cells with stable MDR and increased metastatic capacity.

PMID:
23499896
PMCID:
PMC3669644
DOI:
10.1016/j.canlet.2013.02.059
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center